Glioma

This phase 1 trial tests a new approach for diffuse midline glioma (DMG), an aggressive brain tumor with a poor prognosis. The treatment combines focused ultrasound to temporarily open the blood-brain barrier with an infusion of immune cells engineered to attack the tumor. The st…

Researchers are testing a new cell therapy called GD2-CART01 in children and young adults with brain or central nervous system tumors that have come back or stopped responding to treatment. The therapy uses the patient's own T cells, modified to recognize a marker called GD2 on t…

Researchers are testing whether a vaccine made from a patient's own dendritic cells can help treat glioblastoma, an aggressive brain cancer. Adults with newly diagnosed glioblastoma who are having surgery will be randomly assigned to receive the vaccine plus standard care or stan…

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

This early-phase trial is testing a new type of cell therapy called GD2 CAR-T cells in children and young adults with diffuse midline glioma, a rare and aggressive brain tumor. The treatment involves collecting the patient's own immune cells, modifying them to recognize and attac…

This trial tests a new gene therapy called TGX-007 for people with a fast-growing brain cancer called glioblastoma. The therapy uses a harmless virus to deliver two special instructions: one helps a common drug kill cancer cells, and the other wakes up the immune system to attack…

This large international trial is testing several different drugs, including temozolomide, lomustine, regorafenib, and paxalisib, in people with newly diagnosed or recurrent glioblastoma, an aggressive brain cancer. The study uses an adaptive design, meaning it can quickly drop i…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This study tests a new way to deliver radiation therapy for glioblastoma, a fast-growing brain tumor. Instead of treating a large area, doctors use MRI-guided adaptive radiation to focus more precisely on the tumor with reduced margins. The goal is to see if this approach can bet…

This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…

This early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.

This early-phase trial tests the safety of a new treatment for people with recurrent or progressive high-grade glioma, a serious brain cancer. The therapy uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells, and delivers them directly into t…

This phase II trial is testing the drug selinexor in people with Wilms tumor, rhabdoid tumor, MPNST, or other solid tumors that have returned or not responded to treatment. Selinexor works by blocking a protein called XPO1, which is often overactive in these cancers. The study ai…

This study tests an experimental drug called ACT001 in children and young adults (ages 1 to 39) with two aggressive brain tumors: DIPG and H3K27-altered high-grade gliomas. The goal is to see if ACT001 can improve survival or shrink tumors after radiation therapy. About 60 partic…

This Phase 2 trial tests whether adding the experimental drug silevertinib to standard chemotherapy (temozolomide) helps people with a specific type of newly diagnosed glioblastoma live longer without their cancer worsening. The study includes 162 participants whose tumors have c…

This study tests whether adding the drug selinexor to standard chemotherapy (temozolomide) can better control recurrent glioblastoma, an aggressive brain cancer. About 97 adults whose tumor has returned after initial treatment will receive either the combo or chemotherapy alone. …

This study looks at whether patients with a certain type of slow-growing brain tumor (low-grade glioma with a BRAF V600 mutation) can safely stop or reduce their dose of two targeted drugs, dabrafenib and trametinib, after 12-24 months of treatment. About 96 participants will eit…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This phase 1 trial tests a new type of immunotherapy for people with recurrent or progressive high-grade gliomas, including glioblastoma. The treatment uses the patient's own T cells, which are genetically modified in the lab to target a protein called IL13Rα2 found on tumor cell…

This early-phase study tests a new drug called ARC101 in 70 people with advanced solid tumors that have a specific marker (Claudin 6). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must have ovarian, testicular, or ot…

This phase 3 trial tests whether the drug ONC201 works better than everolimus for children and adults with DIPG, a rare and aggressive brain tumor. About 433 participants will receive one of the two drugs, and can switch if their disease gets worse. The goal is to see which drug …

This study tests an experimental drug called BMS-986482, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 413 adults will take part. Th…

This study tests an experimental drug called DB-1311/BNT324 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 862 adults will take pa…

This early-stage trial is testing a combination of two immunotherapy drugs, D2C7-IT and 2141-V11, for people with recurrent glioblastoma, a fast-growing brain cancer. The treatment is delivered directly into the brain after surgery, followed by injections near the neck to boost t…

This early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…

This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This study tests a new drug called HYP-6589, alone or with other cancer drugs, in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the drug is safe and shrinks tumors. About 115 adults aged 18–80 with certain genetic marker…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This early-phase trial tests the safety and best dose of the drug triapine when given together with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that cancer cells need to grow, while radiation kills cancer cells …

This study tests a new treatment called BCB-276 for children and young adults with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. BCB-276 is made from a patient's own immune cells, which are modified in a lab to recognize and attack the cancer. The tr…

This phase II trial is testing whether three antibody-drug conjugates (ADCs) can shrink advanced or metastatic solid tumors that have high levels of specific proteins (Trop-2, nectin-4, or HER2). About 500 patients will first have their tumors tested for these markers, then recei…

Researchers are testing YB1-X7, an engineered Salmonella bacteria designed to collect in oxygen-starved tumor tissue and release a payload that kills cancer cells. The trial enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatment or l…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This study tests whether metformin, a common diabetes medicine, can help children and young adults with a rare brain tumor called PFA ependymoma that has come back. About 30 participants will take metformin and have surgery and imaging to see if the drug changes certain proteins …

This study tests an experimental drug called safusidenib in people with a slow-growing brain tumor (IDH1-mutant glioma) whose tumor got worse while on the standard drug vorasidenib. Up to 40 participants take safusidenib pills twice daily to see if the tumor shrinks or stops grow…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This study tests an experimental oral drug called FMC-376 in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change called KRAS G12C. The trial has three parts: first, finding the safest dose; then, checking how well th…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study tests a drug called zotiraciclib in people with a certain type of brain tumor (glioma) that has come back after treatment. The tumor must have a specific gene mutation (IDH1 or IDH2). Participants take the drug by mouth in cycles. The goal is to see if the drug can slo…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This study gives people who are already benefiting from the cancer drugs encorafenib and/or binimetinib in earlier trials continued access to these medicines for up to 5 years. It includes safety monitoring and is open to about 46 participants whose doctors confirm they are still…

This study tests the safety of a wearable device called Optune that creates low-intensity electric fields to disrupt cancer cell division in brainstem gliomas. Ten adults with this rare brain tumor will wear the device to see if it can slow tumor growth without serious side effec…

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

Researchers are running a Phase I trial of BA1203, an experimental drug given intravenously every two weeks, in adults with advanced solid tumors that have worsened after standard treatments. The study aims to find out whether BA1203 is safe and tolerable, how the body processes …

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests a drug called safusidenib in people with a type of brain tumor (glioma) that has a specific gene mutation (IDH1). The trial has three parts: one for recurrent tumors, one for high-risk tumors after standard treatment, and one for a specific tumor type after surge…

This study tests two experimental immunotherapy drugs, D2C7-IT and 2141-V11, in adults with a newly diagnosed, aggressive type of brain cancer called glioblastoma. The drugs are given directly into the brain after surgery, followed by injections near the neck lymph nodes. The goa…

This study tests an experimental drug called BDTX-1535 in people with aggressive brain tumors (high-grade glioma or glioblastoma) that have certain changes in the EGFR gene. The drug aims to block a growth signal that these tumors rely on. The trial first measures how much drug r…

This study tests the drug abemaciclib, typically used for cancer, in people with neurofibromatosis type 1 (NF1) who have atypical neurofibromas that cannot be surgically removed. The goal is to find a safe dose and see if it can shrink or stabilize these tumors. Participants take…

This early-phase trial tests a new way to give radiation to people whose glioblastoma (a severe brain cancer) has come back after initial treatment. About 28 adults will receive focused radiation over 1 to 3 weeks, with different schedules to find the safest dose. The goal is to …

This early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …

This early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This study tests a new drug called LMP744 in people whose glioblastoma has come back after standard treatment. The drug is designed to kill cancer cells by blocking a key growth signal and interfering with DNA repair. Participants will receive the drug through a vein for 5 days e…

This study tests a drug called PLX038 in adults with brain or spinal cord tumors, including those with changes in the MYC or MYCN genes. The trial has two phases: first, finding the right dose, then checking if it works. Participants receive PLX038 intravenously every three weeks…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

Researchers are testing an experimental oral drug called XNW29016 in adults with advanced solid tumors that have not responded to standard treatment. The trial has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look at early signs of activity…

This study tests a combination of two drugs, mirdametinib (taken by mouth) and vinblastine (given through a vein), in children and young adults with a type of brain tumor called low-grade glioma that has a specific genetic change (MAPK pathway activation). The trial has three par…

This study tests an experimental drug called JAB-23E73, taken as a pill, in adults with advanced solid tumors that have a KRAS alteration. The trial has three parts: first finding a safe dose, then optimizing it, and finally checking if the drug shrinks tumors in certain cancers …

This early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and malignant peripheral nerve sheath tumors. The goal is to find the safest dose and see if it can shrink tumors or slow disease. Participants receive …

Researchers are testing a treatment that places radioactive rhenium-186 nanoliposomes directly into recurrent glioma tumors using a thin catheter. The trial enrolls adults whose high-grade brain tumor has returned after surgery, radiation, or chemotherapy. The study first finds t…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This phase 2 trial is testing whether combining an experimental immunotherapy (MK-2010) with an antibody-drug conjugate (sacituzumab tirumotecan) can help people with advanced solid tumors. The goal is to see if the combination is safe and can shrink or eliminate tumors. Particip…

This clinical trial is testing whether adding an experimental drug called WSD0922-FU to standard chemotherapy (temozolomide) can better slow the growth of a specific type of brain cancer called EGFR-mutant glioblastoma. The study involves about 60 adults whose tumors have a parti…

This early-phase trial tests an experimental drug called BSI-082, alone or combined with a standard cancer drug (T-DXd), in 57 adults with advanced or metastatic solid tumors that have not responded to other treatments. The study has two parts: first, finding the safest dose of B…

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This phase 2 trial is testing whether a combination of lenvatinib (a targeted drug) and a PD-1 inhibitor (immunotherapy) can shrink or stop advanced solid tumors that have a specific genetic change called 11q13 amplification. About 60 adults with various cancers like esophageal, …

Researchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…

This phase 2 trial is testing whether adding a special type of radiation called adaptive pulse radiotherapy to standard immunotherapy can help treat advanced solid tumors. The study will enroll 35 people who are already receiving or planning to receive immune checkpoint inhibitor…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to better fight the cancer. Th…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…

Researchers are running a first-in-human Phase I trial of AK157D1, an experimental drug given by intravenous infusion, in adults with advanced solid tumors that have worsened after standard treatment or have no standard options left. The study aims to find out whether the drug is…

Researchers are running a first-in-human Phase 1 trial of BA1106, an experimental intravenous drug, in adults with advanced solid tumors that have worsened after standard treatments. The main goal is to check safety and tolerability, and to see how the body processes the drug. Pa…

Researchers are running a first-in-human Phase 1 trial of BA1302, an intravenous drug, in adults with advanced solid tumors including melanoma, breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. The trial has two parts: a dose-escalation phase to find a saf…

Researchers are testing an engineered interleukin-2 drug called MDNA11 in adults with advanced solid tumors. The trial gives MDNA11 alone or with pembrolizumab, an immune checkpoint inhibitor, to see which doses are safe and how the body processes the drug. It also looks for earl…

This study tests a new drug called HY07121 in 258 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV infusion. The main goals are to check safety, find the right dose, and see if it can shrink tumors. This is an early-stage t…

Researchers are running a first-in-human Phase 1 trial of BA1301, an experimental drug given intravenously every three weeks, in adults with advanced solid tumors that cannot be removed by surgery. The trial enrolls about 70 people aged 18 to 75 whose cancer has progressed after …

This study tests a combination of drugs given in low, frequent doses to slow or stop the growth of recurrent brain tumors in children. The goal is to extend survival while maintaining quality of life. About 232 children with medulloblastoma, ependymoma, ATRT, or other rare CNS tu…

This study tests a virus called G207 combined with a small dose of radiation in children whose high-grade glioma has come back or is growing. The goal is to see if the treatment is safe and helps control the tumor. About 38 children will take part.

This early-stage study is testing a new drug called AT03-65 in 83 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might shrink tumors. Part…

This early-stage trial tests whether personalized immune cells (T-cells) can safely treat young children with aggressive brain tumors. The T-cells are designed to attack unique markers found on each child's tumor. Up to 12 children under 5 with embryonal brain tumors or recurrent…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

Researchers at the Medical University of Warsaw are testing a locally delivered alpha-emitting therapy called [225Ac]Ac-DOTA-SP in adults with recurrent high-grade glioma, a fast-growing brain tumor that often returns after standard treatment. Participants receive up to six cycle…

This study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study tests a new drug called MHB046C in 200 people with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously every three weeks.

Researchers are testing an experimental antibody injection called MHB118C in adults with advanced solid tumors that have not responded to standard treatments. The trial aims to find out whether the drug is safe, what side effects it causes, and what dose people can tolerate. Part…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This early-stage study tests a new drug, APX-343A, alone or with another cancer drug (pembrolizumab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Ab…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This early-phase study tests the safety of an engineered virus called M032 in 20 children and adults with diffuse midline glioma, a rare and aggressive brain tumor. Participants receive the virus directly into the tumor after completing standard radiation therapy. The goal is to …

Researchers are testing a treatment called 5-ALA sonodynamic therapy in adults newly diagnosed with butterfly glioblastoma, a brain tumor that spreads across both sides of the brain. Participants take an oral drug called 5-ALA, then receive ultrasound using the LIDU system, which…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This study tests the drug ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the drug can shrink tumors or improve blood counts. About 70 chil…

This study tests an experimental drug called TRK-950 in people with advanced solid tumors or melanoma that has not responded to standard treatments. The first parts check safety and side effects when given alone or with another cancer drug (nivolumab). The final part looks at whe…

Researchers are testing whether a specialized radiation technique called lattice radiotherapy, combined with PD-1/PD-L1 inhibitor drugs, can safely shrink large tumors in people with advanced solid cancers. The trial enrolls adults whose cancer has progressed after standard treat…

This phase 1 trial tests a drug called 177Lu-DTPA-omburtamab, which delivers radiation directly to tumor cells in children and teens with recurrent or refractory medulloblastoma or other central nervous system (CNS) tumors that have spread. The drug targets a protein called B7-H3…

This early-phase trial is testing a new drug called M3554, which is designed to seek out and attack cancer cells that have a protein called GD2 on their surface. The study will include up to 52 people with advanced soft tissue sarcoma or glioblastoma that has not responded to pri…

This phase 3 trial tests whether the drug vorasidenib can delay tumor progression in people with IDH-mutant grade 2 or 3 astrocytoma after they finish initial chemoradiotherapy. About 468 participants will receive either vorasidenib or a placebo daily. The main goal is to see if …

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

Researchers are testing an experimental oral drug called T-1301 in people with advanced solid tumors or lymphoma that have not responded to standard treatments. The Phase I trial aims to find the highest dose participants can tolerate and the dose best suited for later studies. A…

This early-stage trial tests a new drug called BI 764532 in 20 adults with a type of brain tumor (glioma) that has a specific marker called DLL3 and hasn't improved with prior treatment. The drug is designed to link cancer cells to immune cells, helping the body fight the tumor. …

This Phase 3 trial tests whether adding a special radiation tile (GammaTile) during brain surgery improves survival for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 766 participants will be randomly assigned to standard treatment (surgery, radiatio…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This program provides mirdametinib to individual patients with serious, life-threatening conditions like neurofibromatosis type 1 tumors or other MAP-K pathway diseases who have no other treatment options and cannot join a clinical trial. Each case requires approval from the comp…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This Phase 3 trial tests a device called SonoCloud-9, which uses ultrasound to temporarily open the blood-brain barrier, allowing more carboplatin chemotherapy to reach glioblastoma tumors that have returned after initial treatment. About 560 participants will be randomly assigne…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This Phase III trial is testing whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of brain tumor (IDH-mutated grade 3 astrocytoma). About 408 participants will receive either vorasidenib or a pla…

This study tests whether adding the drug ruxolitinib to standard treatment (radiation and temozolomide) helps people with newly diagnosed glioblastoma live longer. About 190 adults will be randomly assigned to receive either the standard treatment alone or standard treatment plus…

Researchers are testing an experimental intravenous drug called T-1201 in adults with advanced solid tumors that have not responded to standard therapy or have no standard treatment left. The main goals are to find the highest dose people can tolerate and the dose best suited for…

This early-stage trial tests whether two cancer drugs, cabozantinib and selumetinib, can safely shrink plexiform neurofibromas in people aged 16 and older with neurofibromatosis type 1 (NF1). About 30 participants will receive the combination daily. The study first finds the safe…

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

Researchers are testing an experimental oral drug called GH56 in people with advanced solid tumors that have lost the MTAP gene. The trial enrolls adults and adolescents whose cancer has progressed after standard treatment or who have no standard options left. The study first fin…

This phase 2 trial tests a new drug called GI-102, alone or with the immunotherapy pembrolizumab, given before surgery to people with recurrent or progressive glioblastoma (a fast-growing brain cancer). The goal is to see if these drugs can increase cancer-fighting immune cells i…

This early-phase trial at Mayo Clinic is testing combinations of four drugs (dasatinib, quercetin, fisetin, and temozolomide) in 30 adults with previously treated glioma that still has residual tumor cells. The goal is to see if it's feasible to use individual patient data from b…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

Researchers are testing a new oral drug called HTL0039732 in people with advanced solid tumors that have not responded to standard treatments. The trial gives the drug alone and in combination with atezolizumab or other approved cancer therapies. The main goals are to find a safe…

This study tests an experimental drug, hetrombopag, to see if it can safely raise platelet counts in cancer patients whose platelets drop too low after chemotherapy. About 150 adults with solid tumors (like lung, breast, or colon cancer) will receive either the drug or a placebo …

This study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the best dose and check if it is safe and shrinks tumors. All participants get the drug by injection, and the study invol…

This early-stage trial is testing an experimental drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study involves adults with locally advanced or metastatic head and neck tumors or other solid tumors. The main goals are to assess the…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This early-phase trial tests a new type of immune cell therapy for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own natural killer (NK) cells that have been genetically modified to produce IL-15, a protein that hel…

This phase I trial is testing whether giving a single, high dose of radiation (radiosurgery) before surgery can help control high grade glioma, a fast-growing brain tumor. About 28 adults with newly diagnosed or previously biopsied high grade glioma will receive radiosurgery foll…

This early-stage trial tests a new type of immunotherapy for recurrent glioblastoma, an aggressive brain cancer. Researchers take a patient's own T cells and genetically engineer them to recognize and attack cancer cells that carry a protein called GPC3. The cells also include a …

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This early-phase trial is testing whether a new drug called ZEN003694, when added to the chemotherapy capecitabine, is safe for people with advanced solid tumors that have spread or can't be removed by surgery. About 30 participants will receive the combination to find the best d…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-stage study tests a new drug, AUBE00, in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a spec…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-stage trial tests a two-step approach for glioblastoma that has come back after standard treatment. First, doctors use a laser guided by MRI to heat and destroy part of the tumor. Then, within a week, patients take the chemotherapy drug lomustine. The study will enroll…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This early-phase trial is testing a new drug called BHV-1510, either alone or with another drug (cemiplimab), in 500 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors. Because …

This early-phase trial tests a new drug called RPTR-1-201 in 150 adults with advanced solid tumors that cannot be cured with standard treatments. The drug works by helping the body's immune cells attack cancer. The study aims to find the safest dose and see if the drug shrinks tu…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This early study tests a device called TheraSphere GBM in 36 people whose glioblastoma has come back after prior treatment. The device delivers tiny radioactive beads directly to the tumor to try to control it. The main goal is to check if the procedure is safe, not yet whether i…

This early-phase trial tests a modified cold virus (DNX-2401) that is loaded into donor stem cells and injected into the brain's blood supply to target recurrent high-grade gliomas. The virus is designed to infect and kill cancer cells while leaving healthy cells alone. The study…

This study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors, lymphoma, or brain tumors that have specific gene changes (ALK, ROS1, or NTRK1-3). The goal is to find the safest dose and see if the drug shrinks tumors. Particip…

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…

This early-phase study tests a new drug called BH3120, alone or with pembrolizumab, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 245 p…

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

Researchers are running a Phase 1 trial of IBI3001, an intravenous drug, in adults with unresectable, locally advanced or metastatic solid tumors. The study aims to find the highest dose people can tolerate and the dose to use in later trials. Participants receive IBI3001 by infu…

Researchers are testing an experimental drug called IBI3020 in adults with solid tumors that have spread or cannot be removed by surgery. IBI3020 is an antibody-drug conjugate that targets the CEACAM5 protein on tumor cells and delivers two different payloads. The main goals are …

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This early-phase trial tests a new drug called CDR404 in up to 42 adults with advanced solid tumors that have a specific marker (MAGE-A4) and tissue type (HLA-A*02:01). The drug is designed to help the body's immune T-cells find and attack cancer cells. The main goals are to chec…

This early-stage trial is testing a new drug called MTI-301 in 42 adults with advanced solid cancers that have spread or can't be removed and haven't responded to standard treatments. The drug blocks an enzyme called SCD1, which some cancers use to grow and spread. The main goals…

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.…

This study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 326 adults aged 18 to 75 with good overall health will take …

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

Researchers are testing an experimental mRNA injection called ABO2011 in adults with advanced solid tumors that have worsened after standard treatment. The injection delivers genetic instructions for interleukin-12, a protein that can stir up an immune response, directly into the…

This early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 pr…

This early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…

This trial tests an experimental drug called FH-006 in 150 people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if FH-006 is safe, tolerable, and can shrink tumors. Researchers will measure how the drug moves through the body and …

This phase 2 trial tests the safety and feasibility of combining three treatments—tumor-treating electric fields (Optune GIO), MRI-guided laser ablation (NeuroBlate), and the immunotherapy drug pembrolizumab (Keytruda)—in 20 adults with recurrent glioblastoma. Participants receiv…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This study tests a new drug (Debio 0123) combined with standard chemotherapy (temozolomide) and sometimes radiation in adults with glioblastoma, an aggressive brain cancer. The goal is to find the safest dose and see if the combination helps people live longer. About 116 particip…

This early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …

This study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug shrinks tumors. About 160 adults with certain cancer types…

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This early-phase trial is testing whether combining an immunotherapy drug (pembrolizumab) with targeted radiation before surgery is safe and feasible for people with recurrent glioblastoma, an aggressive brain cancer. Ten participants will receive the drug and radiation, then und…

Researchers are testing whether combining valproic acid, irinotecan, and simvastatin can shrink or stabilize recurrent glioblastoma and IDH-mutated glioma tumors. The trial enrolls 52 adults whose tumors have grown after prior treatment with radiation and chemotherapy. Participan…

Researchers at the University of Minnesota are testing whether a single extra dose of radiation, given about four weeks after standard chemotherapy, is safe and practical for adults with newly diagnosed glioblastoma. Participants first receive standard surgery, radiation, and che…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-phase trial tests the safety of a drug called ERAS-801 in 10 adults with recurrent glioblastoma, a fast-growing brain cancer. The drug targets a protein called EGFR that is overactive in many of these tumors. Researchers will also check if the drug affects tumor activi…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This phase 2 trial tests two immunotherapy drugs, nivolumab and relatlimab, in people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 92 participants will receive the drugs before and after surgery to see if they are safe and help the immune system attack th…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, an…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This early-stage trial tests a new treatment for adults with a returning, aggressive brain cancer called glioblastoma. The therapy uses the patient's own immune cells, modified to recognize and attack the cancer, and delivers them directly into the brain. The main goals are to se…

Researchers are testing a vaccine that targets cytomegalovirus (CMV), a virus found in many glioblastoma tumors. The trial enrolls adults with newly diagnosed glioblastoma that lacks MGMT methylation and who have CMV antibodies. Participants receive the PEP-CMV vaccine along with…

This early-phase study tests a new two-drug combination for adults whose high-grade glioma (a fast-growing brain tumor) has returned after standard treatment. The drugs are temozolomide (a chemotherapy pill given daily at low doses) and abexinostat (an experimental drug that may …

This study tests two drugs—tarlatamab and temozolomide—in adolescents and adults with high-grade brain tumors that have a specific marker called DLL3. The goal is to see if the combination is safe and can shrink tumors. About 70 participants will be enrolled across multiple cente…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This study tests a drug called mirdametinib in children, adolescents, and young adults with low-grade glioma, a type of brain tumor. The drug is designed to cross into the brain and block a protein that helps tumors grow. The trial has two phases: Phase 1 finds the safest dose, a…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This study tests a new drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the best dose, check side effects, and see if the drug can shrink tumors. The…

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

Researchers are testing a radioactive gel called rhenium-186 obisbemeda in children and young adults, ages 6 to 21, whose ependymoma or high-grade glioma has come back or keeps growing after treatment. The gel is infused directly into the tumor through a thin tube, a method calle…

This study tests whether a targeted drug called selumetinib works as well as standard chemotherapy (carboplatin and vincristine) for children and young adults with a slow-growing brain tumor called low-grade glioma. Participants must be 2 to 21 years old and have a tumor without …

This study tests a new drug, BAY 3713372, for people with solid tumors that have a specific genetic deletion called MTAP. The drug is designed to kill cancer cells while sparing normal cells. The trial will first find a safe dose, then test how well it works in up to 450 particip…

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This phase III trial tests a new way to deliver radiation called TMPRT, which gives the total dose in short pulses with breaks in between, for people with a newly diagnosed, aggressive brain cancer (MGMT-unmethylated glioblastoma). About 398 adults will be randomly assigned to ge…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This study tests a new approach for people with a recently removed glioblastoma (a fast-growing brain tumor). Doctors take some of the patient's own blood stem cells, add a protective gene (P140K MGMT) to them, and return them to the patient. This allows the use of higher doses o…

This early-stage trial tests a new treatment for people with glioblastoma, an aggressive brain cancer that has come back. The therapy uses special neural stem cells that can find cancer cells in the brain and release a virus that kills them. The main goal is to check the safety o…

This early-stage trial tests whether using focused ultrasound with microbubbles can temporarily open the blood-brain barrier, allowing the immunotherapy drug nivolumab to reach brain tumors more effectively. It includes 30 children and young adults with relapsed diffuse midline g…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This early-phase trial tests two experimental drugs, ABBV-637 and ABBV-155, alone or together with ERAS-801 in people whose glioblastoma has come back after standard treatment. About 60 adults with a specific genetic marker (EGFR amplification) will take part. The main goal is to…

This early-stage trial tests two drugs—triapine and temozolomide—together in people whose glioblastoma has returned. The goal is to find the safest dose and see how well patients tolerate the combination. About 30 adults with recurrent grade 2-4 glioma will take part.

This study tests a daily pill called vorasidenib in 10 teenagers (ages 12 to 17) with a slow-growing brain tumor (grade 2 glioma) that has a specific genetic mutation (IDH1 or IDH2). The goal is to see if the drug is safe, how it affects growth and development, and whether it can…

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This study tests an experimental drug called TNG462 for people with advanced solid tumors that have a specific genetic deletion (MTAP). The drug is taken by mouth and aims to slow or stop tumor growth. The trial has two parts: first, finding the safest dose, and then testing that…

This phase 2 trial is testing an oral drug called ACT001 in 12 adults whose glioblastoma has returned after standard treatment. The study focuses on patients whose tumors have a specific genetic signature (STAT3-high). Researchers will check if the drug can shrink or stabilize th…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This early-stage trial tests genetically engineered natural killer (NK) cells in 25 people with recurrent glioblastoma, an aggressive brain cancer. The cells are designed to resist the tumor's defenses. The main goal is to find a safe dose and check for side effects, while also w…

This early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a small dose of radiation to help …

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This study tests a new approach for a rare and aggressive brain tumor called butterfly glioblastoma, which crosses both sides of the brain and has a very poor outlook. The treatment combines open surgery to remove as much tumor as possible from one side, followed by a minimally i…

This early-phase study tests the safety of a new cell therapy called B7-H3 CAR T cells for children and young adults whose brain tumors have come back or are growing despite standard treatment. The therapy uses the patient's own immune cells, modified to target a protein (B7-H3) …

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This phase 2 trial tests whether placing tiny chemotherapy-releasing seeds directly into the brain after tumor removal can help control glioblastoma, an aggressive brain cancer. About 147 adults with either recurrent or newly diagnosed glioblastoma will receive the seeds plus sta…

This study tests two oral drugs, eflornithine (DFMO) and AMXT 1501, in children and young adults up to age 26 with certain cancers that have come back or not responded to treatment. The cancers include neuroblastoma, brain tumors, and sarcomas. The goal is to find a safe dose and…

This study tests a drug called mirdametinib for people with certain brain or spinal cord tumors (gliomas). The goal is to see if it is safe and can shrink tumors or improve symptoms. About 26 adults will take part, and the drug targets tumors with specific genetic changes.

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests several experimental drugs in people with NF2-related schwannomatosis, a genetic condition that causes non-cancerous tumors on nerves. The goal is to see if these drugs can shrink tumors and control the disease. About 109 participants will receive one of three dr…

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…

This early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…

This trial compares two anti-seizure drugs, levetiracetam and valproic acid, in people with glioma who have had a first seizure. The goal is to see which drug better prevents further seizures over six months. Currently, the choice of drug is based on doctor preference, as there i…

This early-stage trial is testing whether combining a personalized vaccine (PEPIDH1M) with the targeted drug vorasidenib can safely and effectively treat adults with recurrent low-grade gliomas that have a specific IDH1 mutation. Participants receive the drug daily and the vaccin…

This trial is testing whether proton therapy, a more precise form of radiation, can better preserve memory and thinking skills compared to standard photon radiation in people with slow-growing brain tumors (grade 2 or 3 gliomas). Participants will be randomly assigned to receive …

This trial tests whether a daily oral drug called trametinib can better control low-grade gliomas in children and young adults compared to standard weekly vinblastine chemotherapy. The study focuses on patients whose tumors do not have certain genetic changes (BRAF V600 mutation)…

This trial is testing whether adding bortezomib to the standard chemotherapy temozolomide can help people with recurrent glioblastoma, a type of aggressive brain cancer. The study focuses on patients whose tumors have a specific genetic marker (unmethylated MGMT) that often makes…

This early-phase trial is testing whether adding the drug atovaquone to standard radiation therapy is safe and tolerable for children with certain malignant brain tumors, including high-grade glioma, diffuse midline glioma, and medulloblastoma. The study includes two groups: chil…

This trial is testing whether combining two drugs—selumetinib and APG-115—can help people with neurofibromatosis type 1 (NF1) who have nerve sheath tumors that are either pre-cancerous or already cancerous. The study aims to find a safe dose and see if the combination can shrink …

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This study tests a new way to plan brain tumor surgery by creating detailed maps of each patient's brain networks using advanced MRI. Instead of relying only on standard anatomy, surgeons can see the white matter pathways and functional networks that could be affected. The goal i…

This trial investigates whether giving a short course of targeted proton radiation before surgery is safe for people with high-grade gliomas, an aggressive type of brain tumor. Nine participants will receive one of three escalating doses of proton therapy, followed by standard su…

This study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…

This study is testing a new, quick MRI technique called Magnetic Resonance Fingerprinting (MRF) to better tell the difference between a brain tumor coming back and damage from radiation therapy (radiation necrosis). About 90 people will take part, including healthy volunteers, pa…

Researchers are testing whether a specialized MRI technique called three-dimensional magnetic resonance elastography (3D MRE) can measure the stiffness and stickiness of vestibular schwannomas, noncancerous tumors that grow on the nerve connecting the ear to the brain. The study …

This early-stage trial tests a fluorescent dye called panitumumab-IRDye800 that attaches to cancer cells. Before surgery, 30 adults with brain tumors will receive a single infusion of the dye. During their operation, a special camera will detect the dye's glow, helping surgeons d…

Researchers are testing whether ultrasound imaging used during brain tumor surgery can reliably show how much of a tumor has been removed. The study enrolls 100 adults with gliomas, meningiomas, or brain metastases in the upper part of the brain. Surgeons use an ultrasound probe …

Researchers are testing a PET/CT scan that uses a radioactive tracer called 68Ga-CAIX to detect solid tumors. The tracer binds to CAIX, a protein that many solid tumors produce when oxygen is scarce. The study enrolls about 100 adults with suspected or confirmed solid tumors, inc…

This study explores whether tear fluid can be used to detect tumor-related particles in people with glioblastoma, a type of brain cancer. Brain tumors release tiny particles called extracellular vesicles that can be found in spinal fluid, but collecting spinal fluid is invasive a…

This early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …

Researchers are testing a radionuclide probe that targets PD-L1, a protein some tumors use to evade the immune system. Adults with solid tumors such as lung, cervical, breast, melanoma, or gastrointestinal cancers receive the probe and then undergo whole-body PET/CT imaging. The …

Researchers are testing a radioactive tracer called 18F-G1 that binds to granzyme B, a protein released when immune cells attack tumors. Adults with solid tumors or blood cancers who are about to start immunotherapy receive an injection of 18F-G1 and then undergo PET/CT scans. Th…

This early-phase trial at Children's Hospital of Philadelphia is testing whether a radioactive tracer called 18F-Fluciclovine (Axumin) can improve PET-MRI scans for children and young adults with low-grade glioma. About 30 participants will receive the tracer before starting trea…

This study tests whether a handheld device called the MasSpec Pen can tell the difference between cancerous MPNST, benign neurofibromas, and normal tissue during surgery. About 60 people with MPNST or neurofibroma will take part. The goal is to see if the device is safe and accur…

Researchers are testing a radioactive tracer called FMISO with PET/MRI scans to map oxygen levels inside malignant brain tumors. Adults with a suspected glioma receive the tracer by IV, then undergo brain scans that combine PET and MRI, sometimes with contrast dyes. The study che…

This pilot study is testing whether magnetic resonance elastography (MRE), a special type of MRI that measures tissue stiffness, can tell apart radiation necrosis (damage from radiation therapy) from recurrent glioma (tumor regrowth) in patients who have already been treated for …

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

Researchers are studying whether thromboelastography, a blood test that measures clot formation, can predict outcomes for people having surgery for glial brain tumors. The trial enrolls about 100 adults who are scheduled for tumor removal or biopsy. By tracking clotting measureme…

This study tests whether drawing blood directly from veins inside the brain can safely diagnose high-grade glioma, a type of brain cancer. Researchers will compare this liquid biopsy to traditional surgical biopsy. Only 20 adults with suspected or confirmed brain cancer will part…

This study is testing whether a special PET/CT scan using an amino acid tracer can better detect tumors in people with amino acid transport disorders, primary hyperparathyroidism, or glioma. About 500 adults will receive a single injection of the tracer and then get scanned. The …

This study tests whether taking multiple MRI scans before, during, and after standard radiation therapy can help doctors see how tumors change. Researchers will enroll people with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer, or pediatric glioma. The g…

This trial explores whether a PSMA PET scan can detect changes in glioblastoma, an aggressive brain cancer, after treatment with bevacizumab. About 20 adults with IDH-wildtype glioblastoma will receive PSMA scans before and after bevacizumab therapy. The goal is to see if PSMA ex…

This Phase I trial is testing an experimental imaging drug, 203Pb-RMX-VH-PIB, to see how it spreads through the body and how much radiation reaches different organs. The study includes adults with glioblastoma (a type of brain cancer) or pancreatic cancer. Participants receive a …

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

Many people with advanced cancer take opioid pain medicines, which often cause constipation. This trial compares two laxatives, macrogol/electrolytes and magnesium hydroxide, to see which works better at preventing constipation when opioids are started. Adults with advanced cance…

This Phase III trial tests whether American ginseng can reduce fatigue in 160 cancer patients. Fatigue is a common and tough side effect of cancer and its treatment. Participants will take either ginseng or a placebo, and researchers will measure changes in fatigue levels over ti…

Researchers test whether using both fluorescence imaging and ultrasound during brain tumor surgery removes more tumor tissue than fluorescence alone. The trial enrolls 52 adults with newly diagnosed high-grade gliomas or brain metastases. During surgery, doctors use a fluorescent…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

Researchers are comparing two music-based programs to see which may better reduce anxiety in people with advanced cancer. One program pairs participants with a music therapist who uses an AI-powered platform to write songs together. The other has trained staff guide participants …

This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce anxiety, depression, and existential distress in people with advanced cancer. Two hundred participants will receive either psilocybin or an active…

This study is testing a smartphone app called I-STAMP that helps people with advanced cancer keep track of their pain and medications. About 73 participants will use the app and rate how easy it is to use and how helpful it is. The goal is to see if the app can make managing canc…

This study tests a program called ROCKS that helps people with advanced cancer and their family caregivers build optimism, communication skills, and knowledge to discuss advance care planning. 152 patient-caregiver pairs will be randomly assigned to the ROCKS program or usual car…

Researchers are testing whether adding a specialized radiation technique called spatially fractionated radiation therapy (SFRT) to standard palliative radiation helps people with large, inoperable solid tumors feel better. SFRT delivers high doses of radiation in a grid pattern, …

Researchers at Massachusetts General Hospital are testing a coaching program called ASCENT for adults diagnosed with a malignant brain tumor. The program uses acceptance and commitment therapy ideas and involves six one-on-one sessions with a coach. The study asks whether patient…

This study tests a support program called NeuroPathways for people recently diagnosed with a malignant brain tumor. The program includes an information guide and four one-on-one coaching sessions to help patients cope. Researchers want to see if the program is practical and helpf…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This pilot study tests a spiritual care program called PEACE, led by chaplains and clinicians, for people with advanced cancer. The goal is to see if it helps patients whose faith influences their medical decisions. Sixty participants will receive two counseling sessions or usual…

This study tests a program called Focused Acceptance and Commitment Therapy (FACT) for advanced cancer patients who feel anxious about death. 70 participants will attend four weekly 35-45 minute sessions to learn coping skills. The goal is to see if FACT is safe, acceptable, and …

This Phase 3 trial tests whether metformin, a widely used diabetes drug, can improve memory and thinking in children and teens who have finished treatment for a brain tumor. About 140 participants aged 7 to 21 will take metformin or a placebo for 16 weeks. Researchers will measur…

This study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This study is testing a new virtual therapy program called FearLess, designed to help people with primary malignant brain tumors and their caregivers cope with the intense fear that their cancer might come back. The program involves 8 weekly one-on-one video sessions with a thera…

This trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…

This study tests a device called SWAN that guides people through head movements to reduce motion sickness and improve balance. It is for adults with inner ear disorders, motion sickness, or those recovering from vestibular schwannoma surgery. Participants use the device at home f…

This study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

Researchers are testing a small implantable device that delivers tiny amounts of cancer drugs directly into brain tumors to see how the tissue responds. The study enrolls up to 30 people with grade II to IV gliomas who are scheduled for surgery. About three days before tumor remo…

Researchers are studying lixumistat, an experimental oral drug, in adults with newly diagnosed glioblastoma who are scheduled for surgery to remove their tumor. Participants take lixumistat once daily for up to four days before surgery, with dosing possibly extended to six days i…

This study looks at how to set the breathing machine (jet ventilator) during a procedure that destroys tumors with heat or cold. The goal is to find the best air pressure setting to keep patients breathing well while the doctor works precisely. About 560 adults having tumor ablat…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study is testing a device called the AlgometRx Nociometer to see if it can measure pain and other abnormal sensations in people with neurofibromatosis type 1 (NF1). The device uses a small electrode on a finger or toe to send painless signals and a camera to record changes i…

This study follows 269 people with neurofibromatosis type 2 (NF2) for up to 10 years to learn how the disease progresses. Participants will have yearly exams, MRI scans, hearing tests, and blood draws. The goal is to understand tumor growth, hearing loss, and speech or swallowing…

This study collects blood and urine samples from 200 adults with glioblastoma (a type of brain tumor) who are receiving radiation therapy. Researchers want to see if levels of two proteins, VEGF and MMP, can predict whether the tumor will come back within one year. The goal is to…

This study works to improve questionnaires that measure pain, daily activities, and physical function for people with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas. Participants aged 5 and older will give feedback on existing surveys through group discussions or…

This study is developing questionnaires to measure how visible tumors in neurofibromatosis type 1 (NF1) affect patients' appearance concerns. About 110 participants, including children, adults, and caregivers, will complete surveys and join focus groups or interviews to give feed…

Researchers at the Sklifosovsky Institute of Emergency Care are studying how much the brain shifts position during surgery to remove tumors such as gliomas, meningiomas, and metastases. The study enrolls 100 adults aged 18 to 80 whose tumors sit above the tentorium, the membrane …

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

Researchers are measuring the psychological and psychiatric health of adults with glioblastoma or head and neck cancer who are receiving radiotherapy. About 207 participants complete standardized questionnaires and clinician-rated assessments to track distress, mood, anxiety, res…

This study uses advanced MRI scans to better identify parts of brain tumors that are likely to grow back after standard treatment. Researchers will compare these scans with usual methods to see if they can improve radiation planning. About 135 adults with certain brain tumors wil…

This pilot trial tests whether ultra-rapid drug screening and genomic sequencing of tumor tissue can help a specialized tumor board recommend personalized treatment plans for children and young adults with relapsed or recurrent rare brain tumors. Participants undergo surgery to c…

Researchers are following adults with favorable-prognosis brain tumors who receive proton therapy or photon therapy at Dutch centers. The study collects standardized clinical, imaging, and dose data over 10 years to see how often memory and thinking problems occur. The goal is to…

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study tests giving chemotherapy before radiation for people with high-grade gliomas, a type of aggressive brain tumor. The goal is to see if this approach works well and makes MRI scans easier to read, since radiation can change how the brain looks. About 70 adults aged 18-8…

This study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…

Researchers on Reunion Island are building a cohort of adults diagnosed with diffuse glioma, a type of brain tumor, since 2018. The study combines medical records with interviews to describe who is affected, how the cancer presents, and what patients and families go through. The …

This study looks at whether special tests can predict which off-guideline drugs—FDA-approved for other cancers but not for a patient's specific cancer—might work for them. It involves 300 advanced cancer patients whose doctors are willing to try these drugs. The goal is to see ho…

This study is analyzing tumor and blood samples from 10,000 adults with advanced solid tumors or blood cancers to find genetic changes that can be targeted by existing drugs. The goal is to see how often these 'actionable' alterations occur and to guide patients toward personaliz…

This study looks at how radiation to the brain affects memory in children who had a brain tumor. Researchers will test memory and thinking skills in 130 children ages 4 to 12, starting 2 years after radiation and again 2 years later. The goal is to learn which parts of the brain …

This study tests a new combined MRI and PET scan that measures how active brain tumor cells are by looking at their energy use (glycolysis). Researchers will take small tissue samples during surgery to check if the scan matches the tumor's actual biology. The goal is to better id…

Researchers at Erasmus Medical Center are testing whether they can record the activity of individual neurons in the brain tissue surrounding gliomas and other brain tumors during surgery. They use a tiny device called a Neuropixels probe, which is inserted into the peritumoral co…

Researchers are collecting tumor and blood samples from children with diffuse midline glioma or high-risk neuroblastoma who are already receiving radiation as part of their standard care. The goal is to understand the biological mechanisms that make radiation effective against tu…

Researchers are collecting weekly urine samples from adults with solid tumor cancers to look for metabolic changes that occur as death approaches. The study aims to understand the biology of dying and explore whether a test could one day predict the last days or weeks of life. Be…

This study tests whether real-time fMRI neurofeedback can help people with brain tumors (gliomas) shift language activity away from the tumor area before surgery. Only 4 participants will be enrolled to see if the approach is feasible, safe, and acceptable. It is a very early, sm…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study is collecting information from up to 40,000 cancer patients who are receiving radiation therapy. Researchers will track their outcomes to better understand what works and how to reduce side effects. The goal is to improve patient care by learning from real-world treatm…

This study looks at how people with advanced cancer feel about stopping or reducing medications that may no longer help. Researchers will interview about 25 patients and survey 300 more to understand their attitudes and beliefs. The goal is to learn what factors influence their v…

This study collects information from 200 adults in Russia who have neurofibromatosis type 1 (NF1) with plexiform neurofibromas. Researchers will look at patients' age, symptoms, and medical history to better understand the disease. No new treatments are being tested; the goal is …

This study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…

This study looks at the genes in cancer tumors to find mutations that might be important for how the cancer grows. Researchers will use leftover tissue from surgeries or biopsies, along with a blood or saliva sample, to compare cancer genes to normal genes. The goal is to underst…

This study uses focused ultrasound to temporarily open the blood-brain barrier during brain tumor surgery. Researchers will place tiny catheters to sample fluid from different brain areas to see how the barrier affects the tumor environment. Only 6 adults with large brain tumors …

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

Researchers are studying whether body mass index (BMI) is linked to health-related quality of life in people with solid tumors. The trial includes about 1,380 adults with a confirmed solid tumor diagnosis. Participants complete standard quality-of-life questionnaires, and researc…

Researchers are studying tissue removed during standard brain tumor surgery to map the metabolites and gene readouts inside gliomas, which are rare brain tumors. The study includes 220 adults with either IDH wildtype glioblastoma or IDH mutant lower-grade gliomas. The goal is to …

This study tests a lab technique called pharmacoscopy that analyzes a patient's tumor tissue to find which drugs might work best for them. It includes 40 adults with various aggressive or rare brain tumors that have not responded to standard treatments. The main goal is to see if…

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

Researchers at Erasme University Hospital are studying how brain tumors disrupt the normal link between nerve activity and blood flow, a problem called neurovascular uncoupling. The trial enrolls 40 patients with glioblastoma, glioma, or astrocytoma before surgery. Participants u…

This study is testing whether having additional MRI scans during radiation and chemotherapy can help doctors see how a high-grade glioma (a type of brain tumor) is changing. The goal is to use that information to adjust the treatment plan for each patient. About 80 adults with th…

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

This pilot study uses two types of PET scans and a powerful 7Tesla MRI to create a detailed metabolic picture of glioblastoma, an aggressive brain cancer. Researchers will compare scan results with tumor tissue analysis to better understand how the tumor uses energy. The goal is …

This study uses genetic testing of brain tumors from children, adolescents, and young adults (ages 1 to 39) with newly diagnosed high-grade glioma, including DIPG. The goal is to identify specific genetic changes in each tumor and then see if patients can join a treatment trial t…

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…

This study is for people aged 3 and older with neurofibromatosis type 1 (NF1), a genetic condition that often causes noncancerous nerve tumors. About half of people with NF1 get these tumors, and sometimes they turn cancerous. Researchers want to test a new method to predict whic…

This study tests a new way to measure brain metabolism using a special glucose drink and MRI scans. Researchers will compare healthy volunteers and people with glioma (a type of brain tumor) to see if the technique can detect differences in energy use. The goal is to improve imag…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study creates a registry of medical records, scans, and surveys from adults with neurofibromatosis type 1 (NF1) who also have a glioma brain tumor. Researchers will track diagnosis, treatments, and quality of life over time to better understand the disease. The goal is to im…

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This study investigates whether a simple smell test could help predict survival and cognitive decline in adults newly diagnosed with glioblastoma, an aggressive brain cancer. Researchers will measure olfactory function at several points during treatment and compare it with surviv…

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This study follows 50 people with vestibular schwannoma—a benign brain tumor—who are treated with Gamma Knife radiosurgery. Researchers will track balance, dizziness, hearing, and vestibular function using questionnaires and tests before treatment, then at one and three years aft…

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This study explores whether artificial intelligence can analyze MRI scans to detect, map, and characterize gliomas—a common type of brain tumor—without needing an invasive biopsy. Researchers will collect existing MRI and clinical data from about 700 patients across Italy to trai…

This study tests whether advanced MRI and magnetic resonance spectroscopy (MRS) can identify specific genetic mutations in gliomas, the most common type of brain tumor. Researchers will scan about 110 people with suspected or confirmed low- or high-grade gliomas before surgery or…

The goal of this clinical trial is to visualize the possible activation of vestibular centers in the brain using in patiens with unilateral vestibular damage, specifically in patients after vestibular schwannoma surgery. The main questions it aims to answer are: 1. Is there a d…

The NF Registry is a database of patient-reported symptoms, treatments, and experiences with their neurofibromatosis disease. It is a contact registry to relay clinical trial opportunities to targeted patient subgroups, and to supply de-identified disease data to researchers. It …

This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.